Award
NIH Reporter #5R01HL178849-02
Selective B Cell Depletion Using Engineered T Cells As A Curative Treatment For Acquired Thrombotic Thrombocytopenic Purpura
Recipient
National Heart Lung and Blood Institute (NHLBI), part of the NIH
Award Amount
$783,386.00
Ceiling
$783,386.00
Awarded
July 24, 2026
Identifier
5R01HL178849-02
NIH/NHLBI awarded a grant to develop engineered T cells as a curative treatment for acquired Thrombotic Thrombocytopenic Purpura, focusing on pre-clinical evaluation of CAR T cell strategies.
Description
The project focuses on developing engineered T cells for autoimmune disease treatment. It involves pre-clinical evaluation of CAR T cell strategies and aims to provide a curative therapy for Thrombotic Thrombocytopenic Purpura. Funded by NIH/NHLBI.